Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study [Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3? línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o locamente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE]

Next Previous
Trial Profile

Multicenter study of a single arm to evaluate the safety of eribulin in 3rd line chemotherapy for patients with HER2-negative metastatic or locally advanced previously treated with anthracyclines and taxanes: Onsite Study [Estudio multicéntrico de un sólo brazo para evaluar la seguridad de Eribulina en 3? línea de quimioterapia para pacientes con cáncer de mama HER2 negativo metastásico o locamente avanzado tratado previamente con taxanos y antraciclina: Estudio OnSITE]

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eribulin (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Acronyms OnSITE
  • Sponsors Eisai Co Ltd

Most Recent Events

  • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
  • 29 Sep 2016 According to Eisai media release, subanalyses from this study will be presented at the European Society for Medical Oncology (ESMO) Congress.
  • 11 May 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top